secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2021-07-14T23:59:59+00:00
Accession:  0001564590-21-036496
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta signs 12-year lease for 88,106 sq ft manufacturing and HQ facility in South San Francisco
--------------------------------------------------------------------------------

- Monthly base rent starts at ~$564K, escalating to ~$823K; tenant improvement allowance up to $25.2M.
- Facility will support research, development, and commercial manufacturing of NK cell therapy pipeline.
- Expected operational by end of 2023; planned production for pivotal trials and commercial launch.
- Nkarta retains existing 2,700 sq ft cGMP facility for early-stage clinical manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000156459021036496/0001564590-21-036496-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000156459021036496/nktx-8k_20210709.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-036496

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer